A new ophthalmic viscosurgical device (OVD) for use during cataract surgery has received CE Mark approval.
The Healon Endocoat from Abbott, a protective gel formula protects and coats the eye when injected during surgical procedures such as cataract extraction, intraocular lens implantation, corneal transplantation and glaucoma filtration.
For increased patient safety and ease of handling for the surgeon, the delivery system includes a smaller, 25-gauge cannula with guard and a smooth delivery.
Donald Nixon, Surgical Director at TriMed Eye Center, Barrie, Ontario, Canada, commented that use of the equipment “provides me with the stability I need throughout the entire cataract procedure for even the most challenging cases”.
Dispersives such as the Healon OVD are expected to account for 38% of the total OVD market in 2011, according to independent ophthalmic research firm Market Scope.
Healon Endocoat OVD is part of Abbott’s Healon family of OVDs and can be used in combination with any of the other Healon products, such as Healon OVD, Healon GV OVD or Healon5 OVD.
Healon EndoCoat OVD is available in Europe, Canada and New Zealand and is currently under review by the FDA for US approval.
Abbott is a broad-based healthcare company that develops, manufactures and markets pharmaceuticals, medical devices and diagnostics for global markets.